Thank you @Nofar74793338!

Here at the Samuels lab we believe in safety first! #Lentivirus #SafetyFirst #LabLife

Proud of @samuels_yardena for her fascinating plenary session at the @AACR annual meeting in Chicago! A great thank you to the program committee chairs, Drs. Matthew G. Vander Heiden and Lillian L. Siu for this amazing opportunity. @mvh_lab @lillian_siu #AACR25 #AACR2025

Translation dysregulation may serve as a new source for identifying cancer-associated antigens, and may also help to predict responses to checkpoint blockade https://t.co/MX3yfxi2HU  @chen_weller  @samuels_yardena @Samuels_lab #CheckpointBlockade #CancerImmunotherapy

Thrilled to share our work in Cancer Cell! Huge thanks to my PI and mentor @samuels_yardena ,OsnatBartok, and our collaborators @chrismcginnis,@Satpathology , Andreas Schlosser,@EytanRuppin & more. We reveal how impaired translation fidelity enhances anti-tumor immunity!🧵(1/8)

In a study published in @Cancer_Cell, researchers from @Samuels_lab manipulated cancer cells into making themselves visible to the immune system, creating a new approach that gives hope to patients with previously untreatable disease>> https://t.co/V90RKJ6U9M @samuels_yardena

AACR - The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity @AACR @samuels_yardena https://t.co/wJEHfddGg5 #Cancer #CancerResearch #AACR #MedX #MedNews #MedEd #IntratumorHeterogeneity #Medicine #Health #Oncology #OncoDaily

The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity: Yardena Samuels will address this topic in a plenary session on Targeting the Cancer Ecosystem (Tuesday, April 29) at #AACR25. Learn more: https://t.co/DKaZw1uxwc @samuels_yardena

8/8 All this would not be possible without the hard work of Sapir Cohen Shvefel, @joyp_ai @sathpathology @NCIEytanRuppin, @samuels_yardena and colleagues. @weizmannScience #CancerResearch #Immunotherapy

7/8 Our findings suggest that MIF expression is an important determinant of aggressive tumor growth in low-ITH tumors in melanoma and could lead to new strategies for treating patients with homogeneous, high-MIF-expressing tumors that don't respond to immune checkpoint therapy.

6/8 These findings were confirmed using #TCGA melanoma patient data. Overall survival was significantly higher in tumors with low MIF expression.

5/8 #CRISPR knockout screens and Single-cell RNA sequencing showed significantly and consistently higher MIF expression in non-rejected vs. rejected tumors. MIF knockout resulted in smaller tumors, reduced TAM infiltration, higher T cells and less exhaustion phenotype.

4/8 Thus identifying specific factors in the tumors that explain the variance in survival time of patients with low-ITH tumors. Single-cell RNA sequencing revealed that non-rejected tumors had more pro-tumorigenic M2 macrophages and exhausted T cells compared to rejected tumors.

3/8 Using this model, we compared the transcriptomic state of tumor and immune cells in rejected vs. non-rejected tumors upon transplantation and throughout tumor evolution.

2/8 To investigate the mechanism(s) responsible for aggressive tumor behavior in low ITH patients we established a novel mouse experimental system that enabled us to tease apart which TME factors play a role in aggressive tumor growth in low-ITH settings.

1/8 Low intra-tumor heterogeneity (#ITH) is associated with better patient survival, but a significant amount of low-ITH patients exhibited a poor outcome. Our study aimed to identify factors contributing to immune escape in these tumors.

Our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @CD_AACR (full study here: https://t.co/8JiVP0buDq) Step-by-step breakdown of this exciting research follows:

New study in @Samuels_lab, published in Cancer Discovery, reveals a key player in the development of aggressive melanoma tumors: a small immune system protein called Mif. Findings promise to open new directions of therapy >> https://t.co/XP2bgKh1Xm @samuels_yardena

Congratulations to our very own Sapir Cohen Shvefel! Her paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in #melanoma, is now published in @CD_AACR ! Full article here:

Thrilled to share that our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @Cancer Discovery! Find the full study here: